Chiron Pulminiq Gets Pulmonary-Allergy Committee Review June 6
This article was originally published in The Pink Sheet Daily
Executive Summary
Advisory committee review of the immunosuppressant will likely focus on FDA-requested analysis of pivotal data for the lung transplant treatment. Chiron confirms that FDA extended Pulminiq's user fee action date by 90 days, to July 15.
You may also be interested in...
Pulminiq Inhaled Cyclosporine Approval Will Be Delayed
Chiron expects approval of the inhaled cyclosporine Pulminiq to be delayed by three months while FDA reviews additional analyses of pivotal data
Chiron Submits NDA For Inhaled Immunosuppressant Pulminiq For Lung Transplant
The company has requested priority review for the aerosolized cyclosporine product for chronic lung transplant rejection. The Oct. 14 NDA is limited to chronic rejection because pivotal study failed to show significance for acute rejection.
Spectrum’s Iso-Vorin Could Clear FDA For Osteosarcoma By First Quarter
The Irvine, Calif., firm also plans sNDAs for a colorectal cancer claim and an oral formulation of the leucovorin relative.